Methamphetamine use disorder (MUD) is a chronic, relapsing brain condition defined by compulsive meth use despite serious harm to health, relationships, and daily functioning. Meth hijacks the brain’s dopamine reward system, producing intense euphoria followed by severe crashes that drive continued use.
Evidence-based rehab programs address both the neurological and behavioral roots of this disorder. People who complete structured treatment reduce their use, improve their mental health, and rebuild their lives.
Meth floods the brain with dopamine, the chemical that signals pleasure and reward. Over time, the brain adapts by reducing its natural dopamine output. This creates a cycle in which a person needs meth just to feel normal. Long-term use is linked to memory loss, impaired decision-making, anxiety, and psychosis [1].
The good news is that the brain can recover. Brain imaging studies show that dopamine systems partially restore themselves after extended abstinence from meth, which underscores why sustained treatment matters [2].
Withdrawal from meth is not usually life-threatening, but it is uncomfortable and psychologically intense. Common symptoms include extreme fatigue, depression, increased appetite, and strong cravings.
For people with severe use, withdrawal-related depression can increase the risk of self-harm. In these cases, medically supervised detox provides a safe, monitored environment to manage withdrawal before behavioral treatment begins.
No FDA-approved medication currently exists for methamphetamine use disorder. This makes behavioral therapy the foundation of effective meth rehab [1]. The table below summarizes two of the most evidence-based behavioral treatments for meth use disorder and what each one does.
| Treatment | How It Works | Best Evidence For |
| Contingency Management (CM) | Provides small tangible rewards (gift cards, prizes) for drug-free urine tests and treatment attendance | Highest abstinence and retention rates of any behavioral therapy for stimulant use disorders |
| Cognitive Behavioral Therapy (CBT) | Teaches patients to identify triggers, challenge unhelpful thoughts, and build healthier coping skills | Long-term relapse prevention and building self-regulation skills |
Contingency management is the most widely studied approach. Three decades of research show it produces higher abstinence rates than other behavioral therapies for stimulant use disorders, and its effects can last at least one year after treatment ends [3]. Despite this strong evidence, CM remains underused in many treatment settings.
While no medication has received FDA approval for meth use disorder, a landmark NIDA-funded clinical trial published in the New England Journal of Medicine found that combining extended-release injectable naltrexone with oral extended-release bupropion significantly outperformed placebo over 12 weeks [4].
Naltrexone blocks opioid receptors that reinforce drug reward, while bupropion reduces the depression and dysphoria that fuel continued meth use.
The response rates in that trial were modest overall, but the combination showed a statistically significant benefit compared to placebo. Researchers recommend combining this approach with behavioral therapies, such as contingency management, for the best outcomes.
A follow-up analysis also confirmed that the medication combination reduced depressive symptoms early in treatment, which itself predicted lower meth use [5].
The right level of care depends on the person. Two main options exist:
Many people with meth use disorder also live with depression, anxiety, trauma, or other mental health conditions. Treating only the addiction while leaving mental health untreated leads to poorer outcomes and higher relapse rates.
Integrated dual-diagnosis treatment addresses both conditions at the same time, with psychiatry, counseling, and behavioral therapy working together as a team.
Clinical researchers now recognize that reducing meth use is a meaningful treatment outcome even when they have not yet achieved full abstinence.
A 2024 analysis of 13 clinical trials found that people who cut their meth use significantly saw real improvements in depression severity, craving, legal status, and social functioning [6]. This supports a more compassionate and realistic approach to recovery, one that values progress over perfection.
Relapse is common with meth use disorder, as it is with other chronic illnesses such as high blood pressure or asthma. A relapse does not mean treatment has failed. It means the treatment plan may need adjustment. Continued engagement in care is the most important predictor of long-term recovery [2].
For those seeking this level of specialized, integrated care in the San Francisco Bay area, Alta Mira Recovery Programs is a high-end, top-tier residential addiction center specializing in the treatment of substance use disorders and complex co-occurring mental health issues.
Contact our compassionate admissions team to learn more.
| [1] | National Institute on Drug Abuse. (2024, November 20). Methamphetamine. National Institute on Drug Abuse. |
| [2] | National Institute on Drug Abuse. (2020, July 6). Treatment and recovery. National Institute on Drug Abuse. |
| [3] | Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. (2024, November 7). Contingency management for the treatment of substance use disorders: Enhancing access, quality, and program integrity for an evidence-based intervention. ASPE. |
| [4] | Trivedi, M. H., et al. (2021). Bupropion and naltrexone in methamphetamine use disorder. New England Journal of Medicine, 384(2), 140-153. |
| [5] | Mehta, M., et al. (2025). Early change in depressive symptom severity with naltrexone-bupropion combination and its association with reduction in methamphetamine use in ADAPT-2 trial. Journal of Clinical Psychiatry. |
| [6] | National Institute on Drug Abuse. (2024, January 10). Reduced drug use is a meaningful treatment outcome for people with stimulant use disorders. National Institute on Drug Abuse. |
